Core Scientific, Inc. Common Stock (CORZ)
Official siteTECHNOLOGY • SOFTWARE - INFRASTRUCTURE • NASDAQ
Market Cap: $4.68B
Last updated: Nov 17, 2026 at 11:05 AM ET
Core Scientific, Inc. Common Stock (CORZ) Financials: Revenue, Profit and Cash Flow
Core Scientific, Inc. Common Stock reported revenue of $319.02M for the fiscal year ended Sep 30, 2025, down 37.5% from the year before. That year, net income was -$288.62M with a net margin of -90.5%, operating cash flow was $278.25M and free cash flow was -$450.75M. The quarter ended Sep 30, 2026 had revenue of $232.87M and net income of $1.18B.
Revenue and Margins
The operating margin was -70.4% in the fiscal year ended Sep 2025, the lowest of the 7 years shown. Over the 6 years to Sep 2025, revenue grew from $59.52M, a compound annual rate of 32.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $319.02M | -37.5% | 11.9% | -70.4% | -90.5% |
| Sep 2024 | $510.67M | +1.6% | 23.7% | -3.8% | -257.5% |
| Sep 2023 | $502.40M | -21.5% | 24.6% | 1.8% | -49.1% |
| Sep 2022 | $640.31M | +17.6% | 1.3% | -38.2% | -335.2% |
| Sep 2021 | $544.48M | +802.7% | 43.9% | 30.6% | 8.7% |
| Sep 2020 | $60.32M | +1.3% | 15.6% | -10.5% | -20.2% |
| Sep 2019 | $59.52M | N/A | 17.7% | -19.6% | -20.0% |
Income Statement
In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $319.02M | $510.67M | $502.40M | $640.31M | $544.48M | $60.32M | $59.52M |
| Cost of revenue | $281.12M | $389.60M | $378.94M | $631.91M | $305.62M | $50.93M | $49.00M |
| Gross profit | $37.90M | $121.07M | $123.46M | $8.40M | $238.86M | $9.39M | $10.53M |
| Research and development | $0 | $11.83M | $7.18M | $26.96M | $7.67M | $5.27M | $5.48M |
| Operating income | -$224.55M | -$19.20M | $8.96M | -$244.57M | $166.64M | -$6.33M | -$11.69M |
| Net income | -$288.62M | -$1.32B | -$246.49M | -$2.15B | $47.31M | -$12.21M | -$11.92M |
| EBITDA | -$207.85M | N/A | N/A | N/A | N/A | $1.63M | -$5.57M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $232.87M | $164.20M | $115.24M | $79.76M | $81.10M | $78.63M | $79.53M | $94.92M | $95.35M | $141.10M | $179.29M | $141.93M |
| Gross profit | $123.27M | $70.04M | $29.75M | $20.88M | $3.78M | $5.03M | $8.21M | $4.76M | -$156.00K | $38.82M | $77.65M | $39.30M |
| Operating income | $72.35M | -$72.13M | -$23.74M | $13.00M | -$65.45M | -$26.28M | -$47.03M | -$39.78M | -$41.22M | $6.58M | $55.23M | $3.93M |
| Net income | $1.18B | -$1.16B | -$347.19M | $214.15M | -$146.66M | -$936.80M | $576.25M | -$265.54M | -$455.26M | -$804.90M | $210.69M | -$195.69M |
Balance Sheet
As of Sep 2025, long-term debt of $1.06B exceeded cash and equivalents by $748.95M. Shareholder equity was negative, at -$962.74M, as total liabilities of $3.31B exceeded total assets of $2.35B.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $2.35B | $1.60B | $712.16M | $807.69M | $2.44B | $225.58M | $162.01M |
| Current assets | $895.54M | $903.96M | $97.02M | $85.10M | $756.56M | $70.92M | $11.05M |
| Cash and equivalents | $311.38M | $836.20M | $50.41M | $15.88M | $117.87M | $8.67M | $6.66M |
| Total liabilities | $3.31B | $2.42B | $1.31B | $1.22B | $1.10B | $91.88M | $26.16M |
| Short-term debt | N/A | $27.93M | $144.21M | N/A | $104.45M | $18.16M | $2.22M |
| Long-term debt | $1.06B | $1.07B | $684.08M | N/A | $652.21M | $19.86M | $2.09M |
| Shareholder equity | -$962.74M | -$820.18M | -$596.94M | -$409.35M | $1.34B | $133.70M | $135.85M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.94B | $5.26B | $3.07B | $2.35B | $2.30B | $1.98B | $1.63B | $1.60B | $921.85M | $761.46M | $813.97M | $712.16M |
| Total liabilities | $7.03B | $7.68B | $4.38B | $3.31B | $3.42B | $3.04B | $1.81B | $2.42B | $1.65B | $1.85B | $1.13B | $1.31B |
| Cash and equivalents | $803.94M | $1.77B | $1.01B | $311.38M | $453.44M | $581.35M | $697.94M | $836.20M | $253.02M | $96.12M | $98.13M | $50.41M |
| Shareholder equity | -$1.09B | -$2.42B | -$1.31B | -$962.74M | -$1.13B | -$1.06B | -$181.51M | -$820.18M | -$729.39M | -$1.08B | -$318.51M | -$596.94M |
Cash Flow
In the fiscal year ended Sep 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $278.25M | $42.90M | $65.11M | $205.19M | -$56.73M | -$23.77M | -$832.00K |
| Capital expenditures | $729.00M | $94.96M | $16.16M | $601.66M | $59.27M | $1.57M | $37.41M |
| Free cash flow | -$450.75M | -$52.06M | $48.95M | -$396.47M | -$116.01M | -$25.33M | -$38.24M |
| Investing cash flow | -$740.75M | -$95.19M | -$3.00M | N/A | -$423.84M | -$15.14M | -$37.36M |
| Financing cash flow | -$63.10M | $819.57M | -$44.65M | $306.15M | $603.53M | $40.72M | $28.69M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $65.29M | -$18.93M | $249.88M | $153.07M | $131.78M | $34.00M | -$45.04M | $13.80M | $5.71M | $1.20M | $22.17M | $21.70M |
| Capital expenditures | $540.74M | $565.02M | $389.23M | $274.81M | $254.62M | $121.28M | $84.02M | $28.76M | $31.05M | $3.13M | $31.89M | $11.64M |
| Free cash flow | -$475.44M | -$583.95M | -$139.35M | -$121.74M | -$122.84M | -$87.28M | -$129.06M | -$14.95M | -$25.34M | -$1.93M | -$9.72M | $10.06M |
Frequently Asked Questions About CORZ
What is Core Scientific, Inc. Common Stock's annual revenue?
Core Scientific, Inc. Common Stock reported revenue of $319.02M for the fiscal year ended Sep 30, 2025.
How fast is Core Scientific, Inc. Common Stock's revenue growing?
Revenue was down 37.5% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -20.7%.
Is Core Scientific, Inc. Common Stock profitable?
No. Core Scientific, Inc. Common Stock reported net income of -$288.62M for the fiscal year ended Sep 30, 2025, with a net margin of -90.5%.
How much free cash flow does CORZ generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of $278.25M minus capital expenditures of $729.00M produced free cash flow of -$450.75M.
How much debt does Core Scientific, Inc. Common Stock have?
The balance sheet dated Sep 30, 2025 reported long-term debt of $1.06B and cash and equivalents of $311.38M.
CORZ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors